[ Main Page | Editorial Board | About | Instructions ]
[ Table of Contents | Archive | Archive Search | Online Submission | E-mail ]

Turkish Journal of Cancer
1995, Volume 25, Number 4, Page(s) 161-167
[ Summary ]
Risk of therapy related acute myeloid leukemia following treatment with epipodophyllotoxins in Langerhans cell histiocytosis
MÜNEVVER BÜYÜKPAMUKÇU1, SEMHA BERBEROĞLU2, FAİK SARIALİOĞLU3, CANAN AKYÜZ1, TEZER KUTLUK1, İNCİ İLHAN2
Departments of Pediatric Oncology, 1Hacettepe University Institute of Oncology, Ankara
2Oncology Hospital, Ankara
3Dokuz EyIül University Institute of Oncology, İzmir-Turkey

Sixty-five children with biopsy-proven Langerhans cell histiocytosis (LCH) were managed at the Department of Pediatric Oncology, Hacettepe University from 1986 to 1992. Sixteen were treated with etoposid (VP-16). Eight received VP-16 as first line therapy and eight as second, third or fourth choice. Patients ranged in age from seven months to eleven years (median 31 months). Male:female ratio was one. The median total dose of VP-16 was 2850 mg/m2 (range 1500-4950 mg/m2) and the median time from the beginning of therapy was 34 months (range 20-46 months). Schedule of drug administration was once every three weeks. None of the patients, whether receiving VP-16 alone or being treated with other chemotherapeutics, developed secondary malignancy although enough time has passed as reported in the literature. No clear conclusion can be drawn in favor of any increased risk for LCH children treated with VP-16.

[ Summary ]
[ Main Page | Editorial Board | About | Instructions ]
[ Table of Contents | Archive | Archive Search | Online Submission | E-mail ]